Cytokinetics (CYTK) Misses Q3 EPS by 35c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $68.78 -1.63%
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.52), $0.35 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $3.16 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
